-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
The Goldman Sachs Group Begins Coverage on LumiraDx (NASDAQ:LMDX)
The Goldman Sachs Group Begins Coverage on LumiraDx (NASDAQ:LMDX)
The Goldman Sachs Group initiated coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research report report published on Monday, The Fly reports. The brokerage issued a neutral rating on the stock.
Separately, Raymond James cut their target price on shares of LumiraDx from $4.00 to $3.50 and set an outperform rating on the stock in a research note on Friday, November 11th.
Get LumiraDx alerts:LumiraDx Price Performance
Shares of LMDX opened at $0.94 on Monday. LumiraDx has a fifty-two week low of $0.77 and a fifty-two week high of $10.42. The firm's 50 day moving average price is $1.09 and its 200 day moving average price is $1.63. The company has a market cap of $42.46 million, a P/E ratio of -0.66 and a beta of 1.05. The company has a quick ratio of 1.63, a current ratio of 2.91 and a debt-to-equity ratio of 20.12.
Institutional Investors Weigh In On LumiraDx
A number of large investors have recently modified their holdings of the company. Balyasny Asset Management LLC increased its position in shares of LumiraDx by 36,072.9% in the 3rd quarter. Balyasny Asset Management LLC now owns 3,771,385 shares of the company's stock valued at $3,847,000 after purchasing an additional 3,760,959 shares during the last quarter. Pathstone Family Office LLC purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $47,000. Bill & Melinda Gates Foundation purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $14,600,000. Citadel Advisors LLC purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $39,000. Finally, Seven Grand Managers LLC purchased a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $191,000.About LumiraDx
(Get Rating)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
Further Reading
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
The Goldman Sachs Group initiated coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research report report published on Monday, The Fly reports. The brokerage issued a neutral rating on the stock.
據The Fly報道，高盛在週一發佈的一份研究報告中首次對LumiraDx(納斯達克代碼：lmdx-Get Rating)的股票進行了報道。該券商對該股的評級為中性。
Separately, Raymond James cut their target price on shares of LumiraDx from $4.00 to $3.50 and set an outperform rating on the stock in a research note on Friday, November 11th.
另外，雷蒙德·詹姆斯在11月11日星期五的一份研究報告中將LumiraDx的目標價從4.00美元下調至3.50美元，並對該股設定了表現優於大盤的評級。
LumiraDx Price Performance
LumiraDx性價比
Shares of LMDX opened at $0.94 on Monday. LumiraDx has a fifty-two week low of $0.77 and a fifty-two week high of $10.42. The firm's 50 day moving average price is $1.09 and its 200 day moving average price is $1.63. The company has a market cap of $42.46 million, a P/E ratio of -0.66 and a beta of 1.05. The company has a quick ratio of 1.63, a current ratio of 2.91 and a debt-to-equity ratio of 20.12.
週一，LMDX的股價開盤報0.94美元。LumiraDx的52周低點為0.77美元，52周高位為10.42美元。該公司的50日移動均線價格為1.09美元，200日移動均線價格為1.63美元。該公司市值為4246萬美元，本益比為-0.66，貝塔係數為1.05。該公司的速動比率為1.63，流動比率為2.91，債務權益比為20.12。
Institutional Investors Weigh In On LumiraDx
機構投資者參與LumiraDx
About LumiraDx
關於LumiraDx
(Get Rating)
(獲取評級)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
LumiraDx有限公司是一家醫療診斷公司。該公司專注於通過向醫療保健提供者提供關鍵診斷資訊來轉變基於社區的醫療保健。它製造和銷售一種診斷平臺，該平臺支持各種測試，在護理點具有實驗室可比的性能。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- 免費獲取StockNews.com在LumiraDx(LMDX)上的研究報告
- 你買下Palantir的決定可能只是個時間問題
- 卡特彼勒和迪爾準備在2023年重整旗鼓嗎？
- 馬倫汽車公司在i-Go登陸歐洲之際受到震動
- 2023年，太陽會照耀這3只大盤太陽能股嗎？
- Lucid Motors面臨的現實可能會給看漲的看法蒙上陰影
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
接收LumiraDx日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對LumiraDx和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧